Background: There is a lack of evidence about the effectiveness of cognitive behavior therapies (CBT) in settings of routine clinical care as well as in the treatment of panic and comorbid disorders. Methods: We investigated a group-oriented CBT approach for 80 patients with panic disorder including 35 patients with current comorbid major depression. Assessments took place 6 months before treatment, at the beginning and end of treatment, and 1 year later. Structured interviews and multiple clinical self-rating scales were used. Results: Panic patients with comorbid major depression showed higher anxiety-specific and nonspecific pathology. The most striking benefits were in reducing avoidance behavior, while improvements concerning catastrophic beliefs were smaller, but still significant. For most self-rating scale results, patients with and without comorbid depression improved to a comparable degree. However, the end-state functioning of patients with panic disorder and current comorbid depression at admission is significantly lower than for patients with panic disorder alone. Conclusions: The results point to the necessity to develop and improve treatment approaches for patients with comorbidity of panic disorder and current major depression.

Keywords:
Panic disorder, Major depression, Comorbidity, Cognitive behavior therapy, Routine clinical care
1.
Arntz A, van den Hout M: Psychological treatments of panic disorder without agoraphobia: Cognitive therapy versus applied relaxation. Behav Res Ther 1996;34:113–121.
2.
Beck JG, Stanley MA, Baldwin LE, Deagle EA, Averill PM: Comparison of cognitive therapy and relaxation training for panic disorder. J Consult Clin Psychol 1994;62:818–826.
3.
Brown C, Schulberg HC, Madonia MJ, Shear MK, Houck PR: Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders. Am J Psychiatry 1996;153:1293–1300.
4.
Clark DM, Salkovskis PM, Hackmann A, Middleton H, Anastasiades P, Gelder M: A comparision of cognitive therapy, applied relaxation and Imipramin in the treatment of panic disorder. Br J Psychiatry 1994;164:759–769.
5.
Fava GA, Zielezny M, Savron G, Grandi S: Long-term effects of behavioural treatment for panic disorders with agoraphobia. Br J Psychiatry 1995;166:87–92.
6.
Margraf J, Barlow DH, Clark DM, Telch MJ: Psychological treatment of panic: Work in progress in outcome, active ingredients, and follow-up. Behav Res Ther 1993;31:1–8.
7.
Öst LG, Westling BE: Applied relaxation vs cognitive behavior therapy in the treatment of panic disorder. Behav Res Ther 1995;33:145–158.
8.
Telch MJ, Lucas JA, Schmidt NB, Hanna HH, Jaimez TL, Lucas RA: Group cognitive-behavioral treatment of panic disorder. Behav Res Ther 1993;31:279–287.
9.
Telch MJ, Schmidt NB, Jaimez L, Jacquin KM, Harrington PJ: Impact of cognitive-behavioral treatment on quality of life in panic disorder patients. J Consult Clin Psychol 1995;63:823–830.
10.
Brown TA, Barlow DH: Long-term outcome in cognitive-behavioral treatment of panic disorder: Clinical predictors and alternative strategies for assessment. J Consult Clin Psychol 1995;63:754–765.
11.
Barlow DH, Lehman CL: Advances in the psychosocial treatment of anxiety disorders. Implications for National Health Care. Arch Gen Psychiatry 1996;53:727–735.
12.
Perry AC, Drummond LM: Medication and psychological treatment for panic disorder: A case of competition or synergy? Curr Opin Psychiatry 1997;10:116–120.
13.
Marks IM, Swinson RP, Basoglu M, Kuch K, Noshirvani H, O’Sullivan G, Lelliott PT, Kirby M, McNamee G, Sengun S, Wickwire K: Alprazolam and exposure alone and combined in panic disorder with agoraphobia. Br J Psychiatry 1993;162:776–787.
14.
Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994;51:8–19.
15.
Magee WJ, Eaton WW, Wittchen HU, McGonagle KA, Kessler RC: Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survery. Arch Gen Psychiatry 1996;53:159–168.
16.
Grunhaus L, Pande AC, Brown MB, Greden JF: Clinical characteristics of patients with concurrent major depressive disorder and panic disorder. Am J Psychiatry 1994;151:541–546.
17.
O’Rouke D, Fahi J, Brophy, Prescott P: The Galway study of panic disorder. III. Outcome at 5 to 6 years. Br J Psychiatry 1996;168:462–469.
18.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 3 rev. Washington, APA, 1987.
19.
Hiller W, Zaudig M, Mombour W: International Diagnostic Check Lists for ICD-10 and DSM-IV. Bern, Huber, 1996.
20.
Hiller W, Zaudig M, Mombour W: Development of diagnostic checklists for use in routine clinical care. Arch Gen Psychiatry 1990;47:782–784.
21.
Marks IM: Behavioural Psychotherapy. Bristol, Wright, 1986.
22.
Champless DL, Caputo GC, Jasin SE, Gracely EJ, Williams C: The mobility inventory for agoraphobia. Behav Res Ther 1985;23:35–44.
23.
Champless DL, Caputo GC, Bright P, Gallagher R: Assessment of fear in agoraphobics: The Body Sensation Questionnaire and the Agoraphobic Cognition Questionnaire. J Consult Clin Psychol 1984;52:1090–1097.
24.
Ehlers A, Margraf J: Fragebogen zu körperbezogenen Ängsten, Kognitionen und Vermeidung. Weinheim, Beltz Test, 1993.
25.
Knight RG, Williams S, McGee R, Olaman S: Psychometric properties of the Center for Epidemiological Studies Depression Scale (CES-D) in a sample of women in middle life. Behav Res Ther 1997;35:373–380.
26.
Hautzinger M, Bailer M: Allgemeine Depressionsskala (ADS). Deutsche Form der ‘Center for Epidemiological Studies Depression Scale’. Weinheim, Beltz, 1993.
27.
Blanes T, Raven P: Psychotherapy of panic disorder. Curr Opin Psychiatry 1995;8:167–171.
28.
Keijsers GPJ, Hoogduin CAL, Schaap CPDR: Prognostic factors in the behavioral treatment of panic disorder with and without agoraphobia. Behav Ther 1994;25:689–708.
29.
Andrade L, Eaton WW, Chilcoat HD: Lifetime co-morbidity of panic attacks and major depression in a population-based study: Age of onset. Psychol Med 1996;26:991–996.
30.
Ehlers A, Breuer P, Dohn D, Fiegenbaum W: Heartbeat perception and panic disorder: Possible explanations for discrepant findings. Behav Res Ther 1995;33:69–76.
31.
Rief W, Hermanutz M: Physiological, attentional, and affective responses to activation and repose in patients with major depression and panic disorder. Br J Clin Psychol 1996;35:605–616.
32.
Laberge B, Gauthier JG, Cote G, Plamondon J, Cormier HJ: Cognitive-behavioral therapy for panic disorder with secondary major depression: A preliminary investigation. J Consult Clin Psychol 1993;61:1028–1037.
33.
Regier DA, Rae DS, Narrow WE, Kaelber CT: Prevalence of anxiety disorders and their comorbidity with mood and addictive disorders. Br J Psychiatry Suppl 1998;173:24–28.
34.
Emmanuel J, Simmonds S, Tyrer P: Systematic review of the outcome of anxiety and depression disorders. Br J Psychiatry Suppl 1998;173:35–41.
35.
Ehlers A: A 1 year prospective study of panic attacks: Clinical course and factors associated with maintenance. J Abnorm Psychol 1995;104:164–172.
36.
Rief W, Heuser J, Mayrhuber E, Stelzer I, Hiller W, Fichter MM: The classification of multiple somatoform symptoms. J Nerv Ment Dis 1996;184:680–687.
37.
Poulton RG, Andrews G: Change in danger cognitions in agoraphobia and social phobia during treatment. Behav Res Ther 1996;34:413–421.
38.
Salkovskis PM, Clark DM, Gelder MG: Cognition-behaviour links in the persistence of panic. Behav Res Ther 1996;34:453–458.
39.
Fava GA, Mangelli L: Subclinical symptoms of panic disorder: New insights into pathophysiology and treatment. Psychother Psychosom 1999;68:281–289.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.